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luoroscopically Guided Implantation
f Modern Cardiac Resynchronization Devices
adiation Burden to the Patient and Associated Risks
ostas Perisinakis, PHD,* Nicholas Theocharopoulos, MSC,*§ John Damilakis, PHD,*
mmanouel Manios, MD,† Panayiotis Vardas, MD, PHD, FESC, FACC,†
icholas Gourtsoyiannis, MD, PHD‡
raklion, Greece
OBJECTIVES To establish radiation risks for patients undergoing fluoroscopically guided cardiac resyn-
chronization device implantation.
BACKGROUND Cardiac resynchonization therapy (CRT) may be associated with extended fluoroscopic
exposure.
METHODS The fluoroscopy time, dose-area product (DAP), exposure parameters, and percentage
contribution of the fluoroscopic projections commonly used were recorded in a series of 14
consecutive patients referred for cardiac resynchronization device implantation and compared
to corresponding data obtained from a control group of 20 patients who underwent a
conventional rhythm device implantation operation. The DAP to peak skin dose, DAP to
effective dose, and DAP to gonadal dose conversion factors were determined for biventricular
pacing and conventional rhythm device implantation using a humanoid phantom and
thermoluminescence dosimetry.
RESULTS The mean total fluoroscopy time and DAP values were 35.2 min and 4,765 cGy cm2,
respectively, for biventricular pacing and 8.2 min and 1,106 cGy cm2, respectively, for
conventional rhythm device implantation. Patient skin dose from biventricular pacing
procedures requiring extended fluoroscopic exposure may exceed threshold dose for the
induction of skin effects only if X-ray source-to-skin distance is kept low. The risk values for
fatal cancer and severe hereditary disorders, respectively, associated with a typical CRT
procedure were 273 per million and 0.2 per million treated patients.
CONCLUSIONS Radiation risks associated with fluoroscopically guided CRT procedures may be considerable.
Present data may be used for the estimation of patient radiation risks from CRT procedures
performed in other institutions. (J Am Coll Cardiol 2005;46:2335–9) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.070American College of Cardiology Foundation
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cardiac resynchronization therapy (CRT) is a proven addi-
ive therapeutic option for patients with severe and drug-
efractory heart failure because it has been found to result in
onsiderable symptomatic improvement and might increase
urvival rates in many patients (1–6). Recent technologic
dvances in leads and generators, coupled with rapidly
xpanding clinical indications, have resulted in a continuous
ncrease in the number of modern resynchronization device
mplantation procedures (7). Implantation procedures for
ardiac resynchronization are commonly performed in the
lectrophysiologic laboratory under fluoroscopic guidance
8). Owing to complexity, these procedures may be pro-
onged, resulting in considerable fluoroscopic exposure (9).
he mean total fluoroscopic exposure involved in CRT with
iventricular pacing has been reported to exceed one hour
10). In recent years, there is growing anxiety regarding
From the Departments of *Medical Physics, †Cardiology, and ‡Radiology, Faculty
f Medicine, University of Crete, Iraklion, Greece; and the §Department of Natural
ciences, Technical Education Institute of Crete, Iraklion, Greece.R
Manuscript received August 5, 2004; revised manuscript received January 13, 2005,
ccepted January 17, 2005.adiation-induced detrimental effects associated with fluo-
oscopically guided interventional procedures that involve
xtended fluoroscopic exposure (11). Electrophysiologists
nd cardiologists are often unaware of the magnitude of the
adiation dose to the skin delivered during cardiac interven-
ional procedures. Besides, apart from increased entrance
kin dose, extended fluoroscopic exposure may result in high
atient effective dose and increased risk for radiation-
nduced carcinogenesis and genetic effects that should not
e overlooked, especially when treated patients are young
ndividuals with long remaining life expectancy (12). To our
nowledge, there are no data in the literature on patient
adiation burden and the associated radiogenic risks follow-
ng fluoroscopically guided implantation of modern cardiac
esynchronization devices.
The aim of the present study was to determine peak skin
ose, effective dose and gonadal dose delivered to patients
ndergoing fluoroscopically guided modern cardiac resyn-
hronization device implantation procedures and evaluate
he radiogenic risk for skin injury, genetic effects, and
arcinogenesis associated with typical CRT procedures.
adiation dose burden and associated risks from CRT were
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hythm device implantation.
ETHODS
atient study. The fluoroscopy time, dose-area product
DAP) and exposure parameters for the posteroanterior
PA), the 30° left-anterior oblique (LAO), and the 30°
ight-anterior oblique (RAO) projections were recorded in a
eries of 14 consecutive patients referred for CRT in the
lectrophysiology laboratory of our institution. Dosimetric
ata were also recorded in a control group of 20 patients
ho underwent conventional pacemaker implantation or an
mplantable cardioverter-defibrillator (ICD) for antibrady-
ardia or antiarrhythmia indications. Implantation proce-
ures were performed by experienced medical personnel
ho are involved in more than 250 implantations per year.
here had been 21 resynchronization devices implanted at
he beginning of the present study. In all study cases, leads,
evices, and implanting materials used were from
edtronic (St. Paul, Minnesota). Access to the coronary
inus was performed after cannulation of the left subclavian
ein using the dedicated tools. Because operators are also
xperienced ablationists, the coronary sinus was rather easily
annulated in most cases by the use of a specially designed
teerable electrophysiology catheter (Livewire; St. Jude
edical, Sylmar, California). Of the 15 consecutive patients
hat were scheduled to be included in the study a satisfactory
eft ventricular (LV) lead position was achieved in 14
atients. In a single patient, angiographic anatomy of the
oronary sinus was not considered appropriate for LV lead
mplantation. This patient was excluded from our analysis.
he CRT ICD was implanted in five and CRT pacemaker
n the other nine treated patients. In two patients of the
RT group no atrial lead was implanted because of persis-
ent atrial fibrillation. A single-lead device was implanted in
our and a dual-lead device in the remaining 16 patients of
he control group.
All studies were performed on a Philips BV-300R2 (Best,
he Netherlands) C-arm fluoroscope. Patient age, height,
nd weight were recorded. The mean percentage contribu-
Abbreviations and Acronyms
cGy cm2  centigray  centimeter2
CRT  cardiac resynchronization therapy
DAP  dose-area product
ICD  implantable cardioverter-defibrillator
ICRP  International Commission on Radiological
Protection
LAO  left-anterior oblique
PA  posteroanterior
RAO  right-anterior oblique
SSD  source-to-skin distance
TLD  thermoluminescence dosimeter
Sv1  sievert1
Gy1  gray1ion of PA, LAO, and RAO fluoroscopic exposures in total rAP was determined for each group of treated patients.
he current study was approved by the local ethics com-
ittee, and informed consent was obtained from all partic-
pants.
adiation dose measurements. Dosimetric data were ob-
ained using an anthropomorphic Rando phantom and
hermoluminescence dosimetry (TLD). The phantom was
oaded with 520 TLD chips to allow for the acquisition of
osimetric data for all radiosensitive organs/tissues as de-
ned by the International Commission on Radiological
rotection (ICRP) (12). Entrance skin dose was monitored
ith use of a 5  10 array of TLDs interspaced by 3 cm
ttached on the beam entrance surface on the posterior of
he phantom thorax with the long side of the array perpen-
icular to phantom axis.
The phantom was exposed to separate fluoroscopy
ourses using the average contribution of PA, RAO ,and
AO projections for each group of participants. Thus,
rgan and effective dose values were separately determined
or: 1) biventricular pacing procedures, and 2) conventional
acemaker or ICD implantation procedures. Each time, the
hantom was exposed to 10,000 cGy cm2 in total, to
ncrease TLD signal and thus reduce the statistical error of
ur measurements.
The DAP to organ dose (dT) conversion factors were
etermined for all radiosensitive organs, and DAP to
ffective dose () conversion factors were estimated accord-
ng to recommendations of ICRP (12) and previously
ublished data (13). The effective dose , gonadal dose, and
eak skin dose to a patient undergoing a cardiac device
mplantation procedure may be estimated from:
EDAP ·  [1]
GDDAP · dgonads [2]
PSDDAP · dentrance skin ·  SSDSSDph
2
[3]
here E is the effective dose, GD is the gonadal dose, PSD
s the peak skin dose, DAP is the total DAP value, and SSD
nd SSDph is the source-to-skin distance during patient and
hantom exposure, respectively.
isks for radiation-induced effects. To evaluate the risk
or radiation-induced skin effects following a device implan-
ation procedure, the peak-skin dose resulting from a typical
rocedure in our institution was compared to 2 Gy, which is
he threshold dose for the induction of skin erythema (14).
he risk for fatal carcinogenesis following a fluoroscopically
uided device implantation was estimated by multiplying
atient effective dose by an average cancer excess mortality
actor of 5 102 Sv1 as recommended by the ICRP (12).
he risk for severe hereditary effects was estimated by
ultiplying gonadal dose by a risk factor of 102 Gy1, asecommended by ICRP (12).
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atient demographic data, total fluoroscopy time, total DAP,
nd percentage contribution of each fluoroscopic exposure
o total DAP are shown in Table 1 for each group of treated
atients. The mean total fluoroscopy time and mean total
AP values were, respectively, 35.2 min and 4,765 cGy cm2
or biventricular pacing and 8.2 min and 1,106 cGy cm2 for
onventional rhythm device implantation procedures.
Exposure parameters of phantom exposures are shown in
able 2. Total DAP to organ dose conversion factors
btained from phantom exposure measurements are pre-
ented in Table 3 for all radiosensitive organs/tissues. The
eak skin, effective, and gonadal dose values delivered to a
atient undergoing typical cardiac rhythm device implanta-
ion procedure in our institution are shown in Table 4. The
-Gy threshold for skin effects is 11 and 44 times higher
han patient peak-skin dose following a typical biventricular
acing procedure and a conventional cardiac rhythm device
mplantation procedure, respectively. The risk values for
atal cancer and severe hereditary disorders associated with a
ypical fluoroscopically guided resynchronization device im-
lantation procedure as performed in our institution are
hown in Table 5 for female and male patients.
able 1. Patient Data and Operating Parameters During Patient
xposures
Cardiac
Resynchronization
Device Implantation
(n  14)
Conventional
Rhythm
Device Implantation
(n  20)
ge (yrs) 59  14 56  17
eight (kg) 75  4 76  7
eight (m) 1.66  0.07 1.68  0.06
luoroscopy time (min) 35.2  21.7 8.2  3.7
AP (cGy cm2) 4765  965 1106  280
A projection
kV 75  5 74  3
mA 2.54  0.21 2.58  0.25
Contribution (%) 70  5 78  3
AO projection
kV 75  5 75  3
mA 2.69  0.16 2.68  0.22
Contribution (%) 21  6 13  2
AO projection
kV 74  5 75  3
mA 2.66  0.20 2.45  0.21
Contribution (%) 9  5 8  2
AP  dose-area product; LAO  left anterior oblique; PA  posteroanterior;
AO  right anterior oblique.
able 2. Phantom Characteristics and Operating Parameters
uring Phantom Exposures
Fluoroscopic Projection kV mA SSD (cm)
A 70 2.56 64
AO 72 2.62 67
AO 70 2.55 63SD  source-to-skin distance; other abbreviations as in Table 1. FISCUSSION
lectrophysiologists rely heavily on fluoroscopy for the
mplantation of modern CRT devices. The current study
as motivated by the absence of dosimetric data regarding
atients undergoing modern fluoroscopically guided CRT
rocedures. Peak skin dose, gonadal dose, and effective dose
ssociated with patients undergoing CRT procedures were
etermined and the corresponding radiation risks were
valuated. Radiation burden and associated risks resulted
rom CRT procedures were compared to corresponding
ata from conventional rhythm device implantation proce-
ures. Present data may be used for the estimation of patient
adiation risks from fluoroscopically guided CRT and con-
entional rhythm device implantation procedures performed
n other institutions.
uantitation of radiation risks associated with CRT
rocedures. According to our findings, radiation burden
nd associated risks to patients undergoing CRT procedures
re four times the corresponding values for patients under-
oing conventional rhythm device implantation procedures.
adiation skin injuries following typical fluoroscopically
able 3. Organ and Effective Dose Values Normalized Over
otal Dose-Area Product
Cardiac
Resynchronization
Device Implantation
[Sv/(cGy cm2)]
Conventional
Rhythm
Device Implantation
[Sv/(cGy cm2)]
onads 0.007 F 0.008 F
0.001 M 0.002 M
ed bone marrow 1.021 1.071
olon 0.114 0.112
ung 3.320 4.234
tomach 0.713 0.752
ladder 0.006 0.011
reast 1.251 1.433
iver 0.525 0.532
sophagus 7.680 8.653
hyroid 0.332 0.373
one tissue 2.268 2.114
kin 0.429 0.484
emainder 0.941 0.996
eak skin dose 38.87 40.82
ffective dose 1.18 F 1.37 F
1.12 M 1.29 M
 female patients; M  male patients.
able 4. Patient Peak Skin Dose, Effective Dose, and Gonadal
ose Following Typical Cardiac Rhythm Device Implantation
rocedures
Cardiac
Resynchronization
Device
Implantation
Conventional
Rhythm Device
Implantation
F M F M
eak skin dose (mGy) 185 45
ffective dose (mSv) 5.6 5.3 1.5 1.4
onadal dose (mGy) 0.033 0.005 0.009 0.002 female patients; M  male patients.
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Radiation Risks From CRT Procedures December 20, 2005:2335–9uided CRT procedures are rather improbable in our
nstitution because the fluoroscopy time threshold for the
nduction of skin lesions was estimated to be 5 h. However,
arge patients are associated with high exposure rate and
onsequently higher radiation burden. Especially, peak-skin
ose would be much higher in large patients because the
ncreased DAP rate is coupled with a lower SSD. Decreas-
ng SSD from 64 cm to 44 cm increases entrance skin dose
y 110%. Thus, radiogenic skin injuries might be induced in
he case of biventricular pacing performed in large patients
ith SSD kept erroneously low during the procedure course.
he nominal risk for cancer induction and genetic disorders
as been reported to be 20% (200,000/million) and 6%
60,000/million), respectively (15). Compared to nominal
isk, the stochastic radiation risk for hereditary effects
ollowing a cardiac rhythm device implantation procedure
ay be considered trivial. Patients with severe heart failure
ave a limited life expectancy and therefore radiogenic
tochastic effects may not appear before the patient suc-
umbs to heart failure. However, the risk for carcinogenesis
ssociated with typical fluoroscopically guided CRT proce-
ures should not be disregarded when treated patients are
oung individuals.
ncertainties in the evaluated radiation risks. The small
umber of patient procedures monitored to obtain data for
he estimation of radiation risks constitutes a limitation for
he current study. Error in the estimated radiation risks may
e attributed to errors associated with thermoluminescence
osimetry and discrepancies between patient fluoroscopic
xposure course and the considered phantom exposure
ourse used to derive conversion factors. The error intro-
uced by thermoluminescence dosimetry has been previ-
usly estimated to be 15% (13), whereas the error due to
eviations between patient and phantom exposure was
stimated to be 10%. The estimated overall error is not
xpected to exceed 20%, which may be considered accept-
ble in evaluating theoretical radiation risks.
he need for universally applicable dosimetric data. Mean
uoroscopy time for conventional cardiac rhythm device
mplantation or extraction has been reported from 3.54 
.3 min by Wiegand et al. (16) to 35  22 min by Tse et al.
17), depending on the device implanted. Mean fluoroscopy
able 5. Risks for Fatal Carcinogenesis and Severe Hereditary
isorders Following Resynchronization Device Implantation
rocedures
Fatal
Cancers per
106 Patients
Hereditary
Disorders per
106 Patients
F M F M
ardiac resynchronization device
implantation
280 265 0.33 0.05
onventional rhythm device
implantation
75 70 0.09 0.02
 female patients; M  male patients.ime for biventricular pacing has been reported as 77  19in by Izutani et al. (10). Apparently, the variability in
uoroscopy times associated with cardiac rhythm device
mplantation procedures reported by different investigators
s considerable. Consequently, there is a need for normal-
zed dosimetric data universally applicable for the estimation
f patient radiation risk following such procedures. The
AP-normalized dosimetric data presented here may be
sed to estimate patient radiation burden from CRT as well
s conventional device implantation procedures performed
t different institutions with use of different equipment and
echnique.
ONCLUSIONS
adiation skin injuries are not to be expected following
uoroscopically guided cardiac resynchronization device
mplantation unless there is inappropriate use of fluoros-
opy. The radiogenic risk for cancer induction should not be
isregarded when treated patients are young individuals.
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edical Physics Department, Faculty of Medicine, University of
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